<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82749">
  <stage>Registered</stage>
  <submitdate>10/04/2008</submitdate>
  <approvaldate>16/04/2008</approvaldate>
  <actrnumber>ACTRN12608000205336</actrnumber>
  <trial_identification>
    <studytitle>Oral sodium bicarbonate to reduce contrast induced nephropathy</studytitle>
    <scientifictitle>Oral sodium bicarbonate to reduce contrast induced nephropathy in the out-patient coronary angiogram population - a randomised, double blinded study in patients with renal impairment</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Coronary artery disease</healthcondition>
    <healthcondition>Renal impairment</healthcondition>
    <healthcondition>Diabetes mellitus</healthcondition>
    <healthcondition>Contrast induced nephropathy</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Sodium bicarbonate capsules (840mg) - doses given day prior to coronary angiography and on the day of procedure.  This is on top of routine pre-angiography intravenous hydration.</interventions>
    <comparator>Control treatment - intravenous hydration prior to coronary angiography.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of contrast induced nephropathy in active and placebo groups</outcome>
      <timepoint>Day 2 and Day 7 renal function assessment from time of angiography</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the rate of contrast induced nephropathy in patients with diabetes mellitus and pre-morbid renal impairment.</outcome>
      <timepoint>Day 2 and Day 7 renal function assessment from time of angiography.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Estimated glomerular filtration rate &lt; 60mL/min
Adults &gt; 18years old
Able to provide informed consent
Awaiting elective coronary angiography</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>New York Heart Association III or IV
Acute myocardial infarction
Acute pulmonary oedema
Pregnancy
Renal replacement therapy
Medical kidney disease (multiple myeloma, acute nephritis)
Prior use of N-acetylcysteine or sodium bicarbonate or intravenous contrast agent in the preceding 4 weeks</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>10/04/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Michael Mok</primarysponsorname>
    <primarysponsoraddress>Cardiology Department
Geelong Hospital
Level 4 Kardinia House
Corner of Ryrie and Bellarine Street
Geelong VIC 3220</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Michael Mok</fundingname>
      <fundingaddress>Cardiology Department
Geelong Hospital
Level 4 Kardinia House
Corner of Ryrie and Bellarine Street
Geelong VIC 3220</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Barwon Health Ethics and Research Committe</ethicname>
      <ethicaddress>Geelong Hospital
Kitcheners House
Ryrie Street
Geelong VIC 3220</ethicaddress>
      <ethicapprovaldate>29/03/2008</ethicapprovaldate>
      <hrec>08/03</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Michael Mok</name>
      <address>Cardiology Department
Geelong Hospital
Level 4 Kardinia House
Corner of Ryrie and Bellarine Street
Geelong VIC 3220</address>
      <phone>+61 3 52267111</phone>
      <fax />
      <email>michaelm@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Michael Mok</name>
      <address>Cardiology Department
Geelong Hospital
Level 4 Kardinia House
Corner of Ryrie and Bellarine Street
Geelong VIC 3220</address>
      <phone>+61 3 52267111</phone>
      <fax />
      <email>michaelm@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Michael Mok</name>
      <address>Cardiology Department
Geelong Hospital
Level 4 Kardinia House
Corner of Ryrie and Bellarine Street
Geelong VIC 3220</address>
      <phone>+61 3 52267111</phone>
      <fax />
      <email>michaelm@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>